Circulacion Sanguinea

Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation : A Report From the Swedish Atrial Fibrillation Cohort Study Leif Friberg, Mårten Rosenqvist and Gregory Y.H. Lip Circulation 2012, 125:2298-2307: originally published online April 18, 2012 doi: 10.1161/CIRCULATIONAHA.111.055079
Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX72514 Copyright © 2012 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/125/19/2298

Data Supplement (unedited) at:http://circ.ahajournals.org/content/suppl/2012/04/13/CIRCULATIONAHA.111.055079.DC1.html

Subscriptions: Information about subscribing to Circulation is online at http://circ.ahajournals.org//subscriptions/ Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail: journalpermissions@lww.com Reprints: Information about reprints canbe found online at http://www.lww.com/reprints

Downloaded from http://circ.ahajournals.org/ by guest on May 16, 2012

Arrhythmia/Electrophysiology
Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation
A Report From the Swedish Atrial Fibrillation Cohort Study
Leif Friberg, MD, PhD; Mårten Rosenqvist, MD, PhD; Gregory Y.H. Lip, MD
Background—Known risk factors for bleedingduring anticoagulant treatment are largely the same as those predicting thromboembolic events in patients with atrial fibrillation (AF). Our objective was to investigate how to maximize the likelihood of avoiding both stroke and bleeding. Methods and Results—All 182 678 subjects with atrial fibrillation in the Swedish Hospital Discharge Register were studied for an average of 1.5 years (260 000patient-years at risk). Patients were stratified according to risk scores with the use of historic International Classification of Disease diagnostic codes in the register. Information about medication was obtained from the Swedish Drug Registry. Our primary end point was net benefit defined as number of avoided ischemic strokes with anticoagulation minus the number of excess intracranial bleedingswith a weight of 1.5 to compensate for the generally more severe outcome with intracranial bleedings. The adjusted net clinical benefit favored anticoagulation for almost all atrial fibrillation patients. The exceptions were patients at very low risk of ischemic stroke with a CHA2DS2-VASc score of 0 and moderately elevated bleeding risk ( 1.7%/y). The results were broadly similar with CHADS2,except for patients with very low embolic risk; the CHA2DS2-VASc was able to identify those patients (n 6205, 3.9% of all patients) who had no net clinical benefit or even some disadvantage from anticoagulant treatment. Conclusions—In almost all patients with atrial fibrillation, the risk of ischemic stroke without anticoagulant treatment is higher than the risk of intracranial bleeding withanticoagulant treatment. Analysis of the net benefit indicates that more patients may benefit from anticoagulant treatment. (Circulation. 2012;125:2298-2307.) Key Words: anticoagulants atrial fibrillation hemorrhage stroke warfarin

trial fibrillation (AF) confers a substantial mortality and morbidity from stroke and thromboembolism. Oral anticoagulation (OAC) therapy with warfarin is highly effectivein reducing stroke and thromboembolism but is associated with increased bleeding risk.1

A

Editorial see p 2285 Clinical Perspective on p 2307
The risk of stroke and thromboembolism in AF is not homogeneous, and various stroke risk stratification schemes have been derived from various risk factors identified from trials and cohort studies2,3 so that high-risk patients can be targeted for...